Insulin prices have skyrocketed in recent years, making it unaffordable for some Americans with diabetes
TUESDAY, June 29, 2021 (HealthDay News) — Walmart said Tuesday that it will start selling its own private brand of insulin at much lower prices than competing products.
Insulin prices have skyrocketed in recent years, making it unaffordable for some Americans with diabetes, according to CBS News. Just three companies — Eli Lilly, Novo Nordisk, and Sanofi — control 99 percent of the market, and there are no generic versions of the drug available.
Walmart’s insulin will cost $72.88 per vial and $85.88 per FlexPen, which is 58 to 75 percent lower than other insulin products on the market. That will save patients $101 per branded vial and $251 per package of branded FlexPens, the company said in a statement, CBS News reported. Novo Nordisk will make Walmart’s private brand insulin.
“We know many people with diabetes struggle to manage the financial burden of this condition, and we are focused on helping by providing affordable solutions,” Cheryl Pegus, M.D., executive vice president of Walmart Health & Wellness, said in a company news release.
Very Low-Carb Diet Shows Greater Cardiometabolic Benefits Than Other Diets .jpg)
Time-Restricted Eating May Help Patients With Type 1 Diabetes 
GLP-1 Receptor Agonist Use Does Not Increase Insulin Discontinuation With Type 2 Diabetes 
Model IDs Inpatients at Risk for Hypoglycemia Within 24 Hours 
Spinal Cord Stimulation Cuts Pain, Improves Sensation With Diabetic Nerve Damage 
Food-Based Support Aids Type 2 Diabetes Outcomes 
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia 
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA 
